Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.

摘要: Of the estimated 130-150 million people who are chronically infected with hepatitis C virus, around 90% reside in low- and middle-income countries. People inject drugs disproportionately affected by HCV, a global prevalence (based on serological reports of HCV antibodies) 67%; world-wide over 10 HCV. Treatment for has improved dramatically recent years arrival new direct acting antivirals (DAAs) this is stimulating considerable efforts to scale up access treatment. However, treatment coverage among general population less than 10% most countries, generally much lower. It that globally 2 need The DAAs offer significant potential rapidly expand While ideal combination therapy remains be established, key characteristics include high efficacy, tolerability, pan-genotypic activity, short duration, oral therapy, affordability, limited drug-drug interactions, availability as fixed-dose combinations once daily treatments. This paper outlines priorities improving drugs: (1) affordable antivirals; (2) increased awareness testing; (3) standardization treatment; (4) simplification service delivery; (5) integration services; (6) peer support; (7) within framework comprehensive prevention; (8) tracking progress; (9) dedicated funding; (10) enabling policies.